Trial Profile
A PHASE 1B, OPEN-LABEL, SAFETY AND TOLERABILITY STUDY OF ORAL MDV3100 IN COMBINATION WITH DOCETAXEL IN MEN WITH ADVANCED PROSTATE CANCER
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Apr 2019
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Docetaxel
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Medivation; Pfizer
- 07 Mar 2018 Status changed from active, no longer recruiting to completed.
- 30 Jan 2018 Planned End Date changed from 1 Jan 2018 to 1 Mar 2018.
- 29 Dec 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.